Affinivax
Latest round
- Series C
Last raised
- Jan 2021
Total raised
- $346M
Investors
- 14
About Affinivax
Affinivax, Inc.Founded in 2014 and headquartered in Cambridge, US, Affinivax, Inc. specializes in vaccine technologies, particularly the Multiple Antigen Presenting System (MAPS™).Affinivax, Inc. specializes in the development of innovative vaccine technologies, particularly targeting pneumococcal diseases.Affinivax generates revenue through the advancement of its vaccine candidates, particularly AFX3772. The company’s structure includes strategic partnerships with healthcare providers and regulatory entities, expecting revenue from milestone payments linked to clinical trial successes.Affinivax plans to leverage the recent acquisition by GlaxoSmithKline to enhance its MAPS platform, allowing for the continued development of a robust pipeline of innovative vaccines.1 billion, the company aims to expedite clinical trials and address significant public health challenges related to pneumococcal disease. Affinivax is focused on expanding its presence in the United States, where it has received Breakthrough Therapy designation for AFX3772, thereby enhancing its market potential.
Who invested in Affinivax
14 investors across 2 rounds
See all investors in Affinivax
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Affinivax
Who invested in Affinivax?
Affinivax has 14 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Affinivax raised?
Affinivax has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Affinivax last raise money?
Affinivax's most recent round on record is a Series C, in Jan 2021.
What does Affinivax do?
Affinivax is a pharmaceuticals company.
Where is Affinivax headquartered?
Affinivax is headquartered in Cambridge, US.
Which VCs invest in companies like Affinivax?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Affinivax's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Affinivax? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.